WuXi PharmaTech Launches Medical Device Testing Services in China

SHANGHAI, Oct. 23, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its Laboratory Testing Division (LTD) has launched preclinical medical device testing services in China. These services are being offered for Chinese and international clients for their product registration with the China Food and Drug Administration (CFDA) and for Chinese clients for product registration in global markets.   

LTD's preclinical medical device testing services in China include a complete portfolio of biocompatibility, microbiology, and chemistry testing services. Major tests being offered include in vitro cytotoxicity; acute, sub-chronic and chronic toxicity; irritation; sensitization; hemocompatibility; implantation; genotoxicity; carcinogenicity; effects on reproduction, including development effects; extractable and leachable testing; and chemical characterization. WuXi has been a leader in providing preclinical and clinical medical device testing services in the United States for many years.

WuXi's operations in Shanghai and Suzhou have successfully passed inspections by the FDA, CFDA, and OECD and audits by many clients for GLP studies. The company has the world-class laboratory and AAALAC-inspected animal facility headed by a highly experienced international management team and staffed by well-trained technicians.

"China's medical device industry is growing rapidly, and WuXi is committed to providing domestic and international medical device companies with the same high quality of testing services in China that we have provided for years in the United States," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This new service offering brings WuXi one step closer to achieving our vision of offering a complete platform of R&D services for global life-science companies."

About WuXi PharmaTech

WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com.

For more information, please contact:

Ronald Aldridge (for investors)
LaVoie HealthScience
+1-617-374-8800 x109
+1 617-792-2459
[email protected]

Aaron Shi (for the media)
Director, Corporate Communications 
WuXi PharmaTech
+86-21-5046-4362
[email protected]

SOURCE WuXi PharmaTech (Cayman) Inc.

Related Links

http://www.wuxiapptec.com